Silo Pharma, Inc.

Contributing Author

Recent Articles by Silo Pharma, Inc.

1 hour	Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal SILO GlobeNewswire
Aug-19	Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway SILO GlobeNewswire
Aug-05	Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform SILO GlobeNewswire
Jul-16	Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 SILO GlobeNewswire
Jul-07	Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 SILO GlobeNewswire
Jun-25	Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market SILO GlobeNewswire
Jun-11	Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears SILO GlobeNewswire
Jun-05	Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset SILO GlobeNewswire
May-21	Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 SILO GlobeNewswire
May-16	Silo Pharma Announces Closing of $2 Million Public Offering SILO GlobeNewswire
May-15	Silo Pharma Announces Pricing of $2 Million Public Offering SILO GlobeNewswire
May-14	Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 SILO GlobeNewswire
May-14	Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories SILO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.